Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Calithera Biosciences, Inc
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have one of the following diseases that is either relapsed or refractory to 2 or more prior treatments:
NHL: At least one measurable lesion
WM: Measurable IgM, with a minimum level of ≥ 2x ULN
MM: Serum M-protein ≥ 0.5 g/dL and/or urine M-protein ≥ 200 mg/24 hr. In Part 2, disease that is considered measurable per the IMWG criteria
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
Life Expectancy of at least 3 months
Adequate hepatic, renal, cardiac and hematological function
You may not be if
Any other current malignancy
Treatment with an unapproved, investigational therapeutic agent, immunotherapy or biological therapy within 21 days prior to the first dose of study drug
Recent bone marrow transplant
Unable to receive medications by mouth
Major surgery within 28 days before the first dose of study drug
Uncontrolled, active infection; patients who are known to have HIV infection/ seropositivity, Hepatitis A, B, or C, or CMV reactivation
Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days prior to the first dose of study drug
Refractory nausea and vomiting or other situation that may preclude adequate absorption
Other conditions that could interfere with treatment
